TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Dec 11, 2020 10:43 JST
Source:
Eisai
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
- If approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimer's disease
- Aducanumab is now under regulatory review in Japan, Europe and the United States
TOKYO, Dec 11, 2020 - (JCN Newswire) - Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer's disease. Aducanumab, an amyloid beta-targeting antibody, has been shown in clinical trials to remove amyloid beta in the brain and significantly slow clinical decline in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease dementia.
"Japan is the third market where we have applied for regulatory approval for aducanumab, and the filing represents continued progress on our commitment to bring this therapy to patients around the world," said Michel Vounatsos, Chief Executive Officer at Biogen. "Japan has met the challenges of a rapidly-aging population by demonstrating global leadership in setting policies that aim to increase support for Alzheimer's disease patients and caregivers. We look forward to the regulatory review of aducanumab with the hope that, if approved, it could help further manage the impact of this devastating disease."
"As Japan has the oldest population in the world, it is anticipated that the social burden of Alzheimer's disease will continue to grow," said Dr. Haruo Naito, Chief Executive Officer at Eisai Co., Ltd. "For more than 30 years, Eisai has been dedicated to dementia research and development, and working with people living with Alzheimer's and their caregivers to fight this disease. The filing of the application is an important step in serving patients and their families as aducanumab may help reduce clinical decline and potentially maintain the ability to live an independent life for as long as possible. Aducanumab also has the potential to help address the public health challenges our aging population faces in Japan."
The Japanese regulatory authority will review the application through the standard review process. In addition to the filing in Japan, aducanumab is under Priority Review with the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2021 and is also under review with the European Medicines Agency.
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
February 22 2021 14:40 JST
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
February 22 2021 12:11 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
February 15 2021 10:07 JST
Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea
February 01 2021 08:35 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
January 26 2021 10:58 JST
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
January 12 2021 11:37 JST
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
December 18 2020 12:09 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
December 17 2020 11:47 JST
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium
December 04 2020 11:17 JST
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
November 30 2020 13:04 JST
More Press release >>
Latest Press Release
Mitsubishi Power Commences Development of World's First Ammonia-fired 40MW Class Gas Turbine System
Mar 01, 2021 18:46 JST
MHI Machine Tool Develops Gear Shaping Machine for High-Precision Small-Module Gears Used in Robots
Mar 01, 2021 18:36 JST
Flying Finn Rovanpera Claims the Championship Lead in the Toyota Yaris WRC
Mar 01, 2021 10:46 JST
BYD to Help Kyoto Reach Japan's 2050 Carbon Neutral Goal
Feb 26, 2021 11:20 JST
Fujitsu and University of Toronto Researchers Develop Quantum-Inspired Technology to Optimize Radiation Treatment Plans for Brain Tumors and Other Diseases
Feb 26, 2021 10:59 JST
DENSO and Yamato Transport Develop D-mobico, Compact Mobile Refrigerator
Feb 25, 2021 19:28 JST
Mazda Production and Sales Results for January 2021
Feb 25, 2021 17:33 JST
Honda Reports Production, Sales and Export Results in January, 2021
Feb 25, 2021 15:27 JST
Toyota's Global Sales and Production Up Year-on-Year in January for Fifth Consecutive Month
Feb 25, 2021 15:12 JST
Chubu Miraiz and MC to Launch New Assisted-Living JV
Feb 24, 2021 14:12 JST
Fujitsu Launches AI-powered Physical Rehabilitation Solution 'HOPE ROMREC' in Japan
Feb 24, 2021 10:39 JST
Toyota Breaks Ground for 'Woven City'
Feb 23, 2021 13:43 JST
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
Feb 22, 2021 15:40 JST
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
Feb 22, 2021 13:11 JST
Northgate Public Services Becomes NEC Software Solutions UK from July 2021
Feb 22, 2021 12:59 JST
TOYOTA GAZOO Racing heads north in search of further snow success
Feb 19, 2021 18:59 JST
Honda Motor Co., Ltd. Announces New President & CEO
Feb 19, 2021 17:23 JST
MITSUBISHI MOTORS Started Operation of a Rooftop Solar Power System at Its Laemchabang Factory in Thailand
Feb 19, 2021 17:05 JST
Activities Report of Hydrogen Utilization Study Group in Chubu
Feb 19, 2021 14:02 JST
OUTLANDER PHEV Became Europe's Best-selling Plug-in Hybrid SUV in 2020
Feb 18, 2021 16:47 JST
More Latest Release >>